2. Search Result
Search Result
Pathways Recommended: Antibody-drug Conjugate/ADC Related
Results for "

CD20 monoclonal antibody

" in MedChemExpress (MCE) Product Catalog:

14

Inhibitors & Agonists

14

Inhibitory Antibodies

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P99855
    Divozilimab

    BCD-132

    		 CD20 Inflammation/Immunology
    Divozilimab (BCD-132) is a humanised monoclonal antibody against CD20 (CD20). Divozilimab can be used for multiple sclerosis research .
    Divozilimab
  • HY-P99538
    Ublituximab

    LFB-R603; TG-1101; TGTX-1101

    		 CD20 Cancer
    Ublituximab (LFB-R603; TG-1101; TGTX-1101) is a next-generation, type 1 chimeric monoclonal antibody targeting a unique epitope on the CD20 antigen. Ublituximab has anticancer effects .
    Ublituximab
  • HY-P99224
    Veltuzumab

    IMMU-106; hA20

    		 Integrin Cancer
    Veltuzumab (IMMU-106) is a humanized anti-CD20 monoclonal antibody. Veltuzumab has low EC50 value of 0.08-0.09 μg/mL in the Daudi cell line. Veltuzumab can be used for the research of cancer including non-Hodgkin lymphoma (NHL) .
    Veltuzumab
  • HY-P9961
    Ofatumumab

    		CD20 Cancer
    Ofatumumab is a fully human anti-CD20 monoclonal antibody that induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity in CD20-expressing B lymphocytes .
    Ofatumumab
  • HY-P9913A
    Rituximab (anti-CD20)
    Maximum Cited Publications
    7 Publications Verification

    		 CD20 Inflammation/Immunology Cancer
    Rituximab (anti-CD20) is an anti-CD20 chimeric monoclonal antibody used to treat certain autoimmune diseases and types of cancer .
    Rituximab (anti-CD20)
  • HY-P9913
    Rituximab
    Maximum Cited Publications
    7 Publications Verification

    Anti-Human CD20 type I, Chimeric antibody

    		 Radionuclide-Drug Conjugates (RDCs) CD20 Inflammation/Immunology Cancer
    Rituximab is an anti-CD20 chimeric monoclonal antibody used for research of certain autoimmune diseases and cancer.
    Rituximab
  • HY-P9910
    Obinutuzumab

    GA101; Anti-Human CD20 type II, Humanized antibody

    		 CD20 Cancer
    Obinutuzumab (GA101) a Type II CD20 humanized IgG1 monoclonal antibody in development for non-Hodgkin lymphoma.
    Obinutuzumab
  • HY-P99326
    Tositumomab

    Anti-Human CD20 Recombinant antibody

    		 Radionuclide-Drug Conjugates (RDCs) CD20 Cancer
    Tositumomab is a murine IgG2a lambda monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B lymphocytes .
    Tositumomab
  • HY-P9960
    Ocrelizumab

    		CD20 Inflammation/Immunology
    Ocrelizumab (Ocrevus) is a humanized anti-CD20 monoclonal antibody. Ocrelizumab can induce B cell depletion and inhibit multiple sclerosis lesions in mice through antibody dependent cytotoxicity (ADCC) .
    Ocrelizumab
  • HY-P99501
    Zuberitamab

    HS006

    		 CD20 Cancer
    Zuberitamab (HS006) is a monoclonal antibody that targets CD20 and can be used in cancer research, including diffuse large B-cell lymphoma .
    Zuberitamab
  • HY-P99308
    Ocaratuzumab

    AME 133v; LY 2469298; Humanized Anti-MS4A1 Recombinant antibody

    		 CD20 Cancer
    Ocaratuzumab (AME 133v) is an Fc-engineered humanized IgG1 anti-CD20 monoclonal antibody, with a Kd of ~100 pM. Ocaratuzumab exhibits more effective antibody-dependent cell-mediated cytotoxicity (ADCC) .
    Ocaratuzumab
  • HY-P99483
    Blontuvetmab

    AT 004; VT 007

    		 CD20 Adenosine Receptor Cancer
    Blontuvetmab (AT 004) is a caninized CD20 monoclonal antibody and is also a potent, selective, highly potent antagonist of A2aR receptor. Blontuvetmab behaves as Nociceptin (HY-P0183)/Orphanin (HY-P0183) FQ receptor (NOP) agonists displaying weak NOP affinity. Blontuvetmab inhibits 5'-N-Ethylcarboxamidoadenosine (NECA)-mediated A2aR activation and significantly reverses the ability of adenosine to suppress CD8 T cell activation, increasing levels of cytokines such as IFN-γ. Blontuvetmab Blontuvetmab can be used for the research of Canine B-cell lymphoma .
    Blontuvetmab
  • HY-P99056
    Utomilumab

    PF 05082566

    		 TNF Receptor Inflammation/Immunology Cancer
    Utomilumab (PF 05082566) is a fully human IgG2 agonist monoclonal antibody that selectively binds to 4-1BB/CD137. Utomilumab can be used in the research of tumors such as follicular and other CD20 + non-Hodgkin lymphomas .
    Utomilumab
  • HY-P99731
    Milatuzumab
    2 Publications Verification

    hLL1; MEDI-115

    		 CD74 Cancer
    Milatuzumab (hLL1; MEDI-115) is a humanized anti-CD74 monoclonal antibody. CD74, a integral membrane protein, is associated with the promotion of B-cell growth and survival. Milatuzumab causes free radical oxygen generation, and loss of mitochondrial membrane potential. Milatuzumaba also decreases CD20/CD74 aggregates and cell adhesion, to lead to cell death .
    Milatuzumab

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: